← Leaderboards
James M Markert
University Of Alabama At Birmingham
$5,310,460
Attributed
$9,103,148
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,103,148 · 9
By mechanism
R01$4,970,561 · 3
U01$2,614,816 · 1
P01$874,072 · 1
M01$398,716 · 3
K08$244,983 · 1
Top collaborators
- Corinne E. Griguer5 shared
- Kevin A Cassady3 shared
- G. Yancey Gillespie3 shared
- Anna C Sorace3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- G. Yancey Gillespie$5,456,344
- Richard J. Whitley$15,110,969
- David T Curiel$31,690,411
- Paul A. Goepfert$51,350,070
- Kevin A Cassady$2,896,264
Others in their field
Top investigators on “Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$49,046,612
- Melissa L Bondy · Stanford University$36,047,564
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
GliomaTumorResponseClinical TrialsImmune ResponsePre-Clinical ModelGenerationsVirusPhase I Clinical TrialsBaseGlioblastomaVirus ReplicationRadiationSafetyMalignant GliomaDesignNeoplastic CellInterleukin-12Gene ExpressionSpecimenEngineeringOncolyticResistanceRecurrence
Grant awards (26)
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma$571,444
R01 · FY2025 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma$542,873
R01 · FY2024 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma$571,444
R01 · FY2023 · CA
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$551,600
R01 · FY2020 · CA · contact PI
Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme$622,670
U01 · FY2019 · NS
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$542,479
R01 · FY2019 · CA · contact PI
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.$478,440
R01 · FY2019 · CA · contact PI
Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme$599,246
U01 · FY2018 · NS
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients$586,155
R01 · FY2018 · CA · contact PI
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.$559,312
R01 · FY2018 · CA · contact PI
Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme$38,231
U01 · FY2018 · NS
Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme$661,640
U01 · FY2017 · NS
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.$566,814
R01 · FY2017 · CA · contact PI
Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme$693,029
U01 · FY2016 · NS
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial$162,922
P01 · FY2013 · CA · contact PI
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial$175,071
P01 · FY2012 · CA · contact PI
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial$175,290
P01 · FY2011 · CA · contact PI
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial$180,677
P01 · FY2010 · CA · contact PI
Lessons from the OR: Using Clinical Biologic Correlates to Inform HSV Trial$180,112
P01 · FY2009 · CA · contact PI
CT 2001 A STAGED PHASE I STUDY OF THE TREATMENT OF MALIGNANT GLIOMA WITH G207,$11,625
M01 · FY2007 · RR · contact PI
CT 2001 A STAGED PHASE I STUDY OF THE TREATMENT OF MALIGNANT GLIOMA WITH G207,$7,050
M01 · FY2006 · RR · contact PI
GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA$175,256
M01 · FY2002 · RR
GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA$175,256
M01 · FY2001 · RR
ENGINEERED HERPES SIMPLEX VIRUS FOR TREATMENT OF GLIOMAS$125,232
K08 · FY2001 · NS
ENGINEERED HERPES SIMPLEX VIRUS FOR TREATMENT OF GLIOMAS$119,751
K08 · FY2000 · NS
GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA$29,529
M01 · FY2000 · RR